Trials / Terminated

TerminatedNCT01076556

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL

Status: Terminated
Phase: Phase 1
Study type: Interventional
Enrollment: 9 (actual)

Sponsor: National Cancer Institute (NCI) · NIH
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This phase I trial is studying the side effects and the best dose of alvocidib when given together with cyclophosphamide and rituximab in treating patients with high risk B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Alvocidib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can also block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Other find cancer cells and help kill them or carry cancer-killing substances to them. Giving cyclophosphamide, alvocidib, and rituximab together may kill more cancer cells.

Detailed description

PRIMARY OBJECTIVES: I. To determine the dose-limiting toxicity and maximum-tolerated dose of treatment with cyclophosphamide, alvocidib, and rituximab in patients with high-risk B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. II. To determine the feasibility of administering this regimen as an outpatient regimen in these patients. SECONDARY OBJECTIVES: I. To determine the complete response rate, partial response rate, and minimal-residual disease-negative response rate in patients treated with this regimen. II. To determine the pharmacokinetics of alvocidib and dexamethasone as part of this regimen. III. To determine the immunologic effects of this regimen as measured by serial T-cell and NK-cell number, T-cell function, and immunoglobulin levels. OUTLINE: This is a dose-escalation study of alvocidib. Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for pharmacokinetic and pharmacodynamic studies. After completion of study treatment, patients are followed up for up to 5 years.

Conditions

Interventions

Type	Name	Description
DRUG	Alvocidib Hydrochloride	Given IV
DRUG	Cyclophosphamide	Given IV
OTHER	Diagnostic Laboratory Biomarker Analysis	Correlative studies
OTHER	Pharmacological Study	Correlative studies
BIOLOGICAL	Rituximab	Given IV

Timeline

Start date: 2010-04-01
Primary completion: 2010-07-01
First posted: 2010-02-26
Last updated: 2015-11-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01076556. Inclusion in this directory is not an endorsement.